Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129337 · ClinicalTrials.gov registry record · Phase 1
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
A Phase 1 study of Tumors, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 6
- Study locations
NCT00129337: Completed Phase 1 study of Tumors, sponsored by Peregrine Pharmaceuticals.
NCT00129337 is a Phase 1 study of Tumors that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 28 participants, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (86% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00129337, a Phase 1 study of Tumors, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there. The effect of bavituximab on tumor responses will also be examined.
Conditions Studied
Interventions
- DRUG Bavituximab
Study Locations (6)
Texas
- University of Texas Southwestern Medical Center - Dallas
- MD Anderson Cancer Center - Houston
- Scott & White Hospital, Center for Cancer Prevention and Care - Temple
Arizona
- Arizona Cancer Center - Tucson
California
- Premiere Oncology - Santa Monica
Tennessee
- The West Clinic - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
What the finished NCT00129337 record still lists
NCT00129337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Bavituximab is the first listed.
NCT00129337 lists 6 locations in 4 states (Texas, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT00129337 about?
NCT00129337 is a clinical study titled "Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies". The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there. The effect of bavituximab on tumor responses will also be examined.
What is the current status of trial NCT00129337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2005-06. Estimated completion is 2009-08.
What conditions does trial NCT00129337 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00129337?
The interventions under investigation include: Bavituximab (DRUG).
Who is sponsoring clinical trial NCT00129337?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00129337 being conducted?
This trial has 6 study locations across Arizona, California, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00129337's enrollment target sits among peer trials
28 16th of 20 higher than 5 of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
-
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia